LONG BEACH, Calif.--(BUSINESS WIRE)--Feb. 16, 2005--Obagi Medical Products (OMP) sponsors two new and exciting clinical studies at the upcoming 63rd Annual American Academy of Dermatology (AAD) Conference in New Orleans. The first of the two studies highlights the results of a 24-week, 301 patient, clinical study of the OBAGI NU-DERM(R) SYSTEM. A summary of the study indicates that the OBAGI NU-DERM SYSTEM is 2-3 times more effective than prescription drug regimens of tretinoin or hydroquinone, and 5-10 times more effective than top physician recommended over-the-counter (OTC) regimens. The results of this study will be on display at Exhibit P203 Friday, February 18th through Sunday, February 20th.
